SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
化学名称: (1R,2R,4S,5S,7s,9s)-9-butyl-7-[[(2S)-3-hydroxy-2-phenylpropanoyl]oxy]-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide (as per EP)
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
微笑: [H][C@]1([N@+]2(CCCC)C)[C@@]3([H])O[C@@]3([H])[C@]2([H])C[C@H](OC([C@@H](C4=CC=CC=C4)CO)=O)C1.[Br-]
Hyoscine Butylbromide EP Impurity F is chemically (1R,2R,4S,5S,7s,9s)-9-butyl-7-[[(2S)-3-hydroxy-2-phenylpropanoyl]oxy]-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide (as per EP). Hyoscine Butylbromide EP Impurity F is supplied with detailed characterization data compliant with regulatory guideline. Hyoscine Butylbromide EP Impurity F can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Hyoscine Butylbromide.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
LC-MS as a Stability-Indicating Method for Analysis of Hyoscine N-Butyl Bromide under Stress Degradation Conditions with Identification of Degradation Products
Nouruddin W Ali , Mohammed Gamal1 * and Mohammed Abdelkawy
Ali et al., Pharm Anal Acta 2013, S7
Simultaneous determination of hyoscine N-butyl bromide and paracetamol in their binary mixture by RP-HPLC method
Nouruddin W. Ali Mohammed Gamal ,Mohammed Abdelkawy
Arabian Journal of Chemistry Volume 10, Supplement 2, May 2017, Pages S1868-S1874
The effect of hyoscine butylbromide in shortening the first stage of labor: A double blind, randomized, controlled, clinical trial
Nourah H Al Qahtani1 and Fatma Al Hajeri2
Ther Clin Risk Manag. 2011; 7: 495–500.
